Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Kura Oncology, Inc.
Sellas Life Sciences Group
Kura Oncology, Inc.
Faron Pharmaceuticals Ltd
Prelude Therapeutics
CellCentric Ltd.
AbbVie
Prelude Therapeutics
AbbVie